Cited by 371Cancer-related Molecular PathwaysHeat shock proteins researchCell death mechanisms and regulation

The DOI matches its Crossref record; 30 of the 37 references it cites were found in a registry or an index.

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Open access

Böttger, Angelika, Böttger, Volker, Sparks, Alison, Liu, Wei-Li, Howard, Stephanie F., Lane, David P.·1997·Current Biology

DOI 10.1016/s0960-9822(06)00374-5

Open this paper in CoChat — free account Open PDF

Abstract

Background The transcriptional activation function of the p53 tumour suppressor protein is induced by DNA damage and results in growth arrest and/or apoptotic responses. A key component of this response is the dramatic rise in p53 protein concentration resulting from an increase in the protein's stability. Very recently, it has been suggested that interaction with the Mdm2 protein may target p53 for rapid degradation. We have designed a gene encoding a small protein that binds tightly to the p53-binding pocket on the Mdm2 protein. We have constructed the gene by cloning a phage display optimised Mdm2-binding peptide into the active-site loop of thioredoxin. Results When introduced into cells containing low levels of wild-type p53, this protein causes a striking accumulation of the endogenous p53 protein, activation of a p53-responsive reporter gene, and cell cycle arrest mimicking the effects seen in these cells after exposure to UV or ionising radiation. Microinjection of a monoclonal antibody to the p53-binding site on Mdm2 achieves a similar effect, establishing its specificity. Conclusions These results demonstrate that the p53 response is constitutively regulated in normal cells by Mdm2 and that disruption of the interaction alone is sufficient to stabilise the p53 protein and activate the p53 response. Our mini protein approach provides a powerful new method to activate p53 without causing DNA damage. More broadly, it establishes a powerful general method for determinin…

Integrity signals

Registry

Crossref · 10.1016/s0960-9822(06)00374-5

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280

Show all 37 references

Sorted by citations

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Understanding protein non-folding
Uversky, V. N., & Dunker, A. K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.01.017 · Cited by 1,221
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses
Rubbi, C. P., & Milner, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg579 · Cited by 828
The MDM2-p53 interaction.
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 778
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742
Self-citation
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage
Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 731
“Moreover, Mdm2 promotes the rapid degradation of p53 (Bottger et al. 1997; Haupt et al. 1997; Kubbutat et al. 1997).”
Background
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
The unfoldomics decade: an update on intrinsically disordered proteins
Dunker, A. K., Oldfield, C. J., Meng, J., Romero, P. R., Yang, J. Y., Chen, J. W., Vacic, V., Zoran Obradovic, A., & Uversky, V. N. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-s2-s1 · Cited by 694
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
SUMO‐1 modification activates the transcriptional response of p53
Rodríguez, M. S., Desterro, J. M. P., Laı́n, S., Midgley, C., Lane, D. P., & Hay, R. T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6455 · Cited by 639
Self-citation
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 635
The cellular response to p53: the decision between life and death
Sionov, R. V., & Haupt, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203130 · Cited by 608
Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study
Bar‐Or, R. L., Maya, R. B.-Y., Segel, L. A., Alon, U., Levine, A. J., & Oren, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210171597 · Cited by 579
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity
Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570
Self-citation
Regulation of the p53 Tumor Suppressor Protein
Oren, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36031 · Cited by 567
Molecular Interaction Map of the Mammalian Cell Cycle Control and DNA Repair Systems
Kohn, K. W. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2703 · Cited by 561
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 522
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2
Dumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455
Regulation of p53 function and stability by phosphorylation.
Ashcroft, M., Kubbutat, M. H. G., & Vousden, K. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1751 · Cited by 452
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433
Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity
Strano, S., Munarriz, E. R., Rossi, M., Castagnoli, L., Shaul, Y., Sacchi, A., Oren, M., Sudol, M., Cesareni, G., & Blandino, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010484200 · Cited by 418
Regulation of p53 stability
Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 411
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414
Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation
Stommel, J. M., & Wahl, G. M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600145 · Cited by 386
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
Self-citation
p53 and breast cancer, an update
Lacroix, M., Toillon, R., & Leclercq, G. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01172 · Cited by 390
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
Unger, T., Juven‐Gershon, T., Moallem, E., Berger, M., Sionov, R. V., Lozano, G., Oren, M., & Haupt, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1805 · Cited by 365
Why target apoptosis in cancer treatment?
Kasibhatla, S., & Tseng, B. (2003) · PubMed · Cited by 350
The role of p53 in chemosensitivity and radiosensitivity
El‐Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337
MDM2 suppresses p73 function without promoting p73 degradation
Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334
The p53 response to DNA damage
Meek, D. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.027 · Cited by 329
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 315
p53 stabilization is decreased upon NFκB activation
Tergaonkar, V., Pando, M. P., Vafa, O., Wahl, G. M., & Verma, I. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00068-5 · Cited by 319
p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products
Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhræus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 305
Mechanisms of p53-mediated apoptosis
Bates, S., & Vousden, K. H. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050267 · Cited by 304
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2
Stevenson, L. F., Sparks, A., Allende‐Vega, N., Xirodimas, D. P., Lane, D. P., & Saville, M. K. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601567 · Cited by 280
Self-citation
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
Midgley, C., Desterro, J. M. P., Saville, M. K., Howard, S. F., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 251
Self-citation
Rational drug design via intrinsically disordered protein
Cheng, Y., LeGall, T., Oldfield, C. J., Mueller, J. P., Van, Y.-Y. J., Romero, P. R., Cortese, M. S., Uversky, V. N., & Dunker, A. K. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.07.005 · Cited by 248
p53-based Cancer TherapyPreprint
Lane, D. P., Cheok, C. F., & Laı́n, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 251
Self-citation
Excess β‐catenin promotes accumulation of transcriptionally active p53
Damalas, A., Ben‐Ze'ev, A., Simcha, I., Shtutman, M. S., Martínez-Leal, J. F., Zhurinsky, J., Geiger, B., & Oren, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3054 · Cited by 239
mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234
Mechanisms of switching on p53: a role for covalent modification?
Meek, D. W. (1999) · Oncogene · doi:10.1038/sj.onc.1202951 · Cited by 238
Activation of p53 in cervical carcinoma cells by small molecules
Hietanen, S., Laı́n, S., Krausz, E., Blattner, C., & Lane, D. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8501 · Cited by 230
Self-citation
Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX
Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 215
Cyclin G Recruits PP2A to Dephosphorylate Mdm2
Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., & Prives, C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00504-x · Cited by 215
Transcription Factor E2F-1 Is Upregulated in Response to DNA Damage in a Manner Analogous to That of p53
Blattner, C., Sparks, A., & Lane, D. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3704 · Cited by 213
Self-citation
Mdm2 binds p73α without targeting degradation
Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212
MdmX Protects p53 from Mdm2-Mediated Degradation
Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211
Isolation of Protein Ligands from Large Peptoid Libraries
Alluri, P. G., Reddy, M. M., Bachhawat‐Sikder, K., Olivos, H. J., & Kodadek, T. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036417x · Cited by 210
Abundance of Intrinsic Disorder in Protein Associated with Cardiovascular Disease
Cheng, Y., LeGall, T., Oldfield, C. J., Dunker, A. K., & Uversky, V. N. (2006) · Biochemistry · doi:10.1021/bi060981d · Cited by 203
Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
Hengstermann, A., Linares, L. K., Ciechanover, A. J., Whitaker, N. J., & Scheffner, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1218 · Cited by 212
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
Mdm2: The Ups and Downs
Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193
Regulation of Mdm2-Directed Degradation by the C Terminus of p53
Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M. A., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5690 · Cited by 193
Comparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189
Self-citation
Identification of a cryptic nucleolar-localization signal in MDM2
Lohrum, M. A. E., Ashcroft, M. A., Kubbutat, M. H. G., & Vousden, K. H. (2000) · Nature Cell Biology · doi:10.1038/35004057 · Cited by 186
Targeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 190
Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction
Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Vrijbloed, J. W., Obrecht, D., & Robinson, J. A. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353242 · Cited by 188
Regulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 184
p53 Activation by Small Molecules: Application in Oncology
Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 174
p53 and chemosensitivity
Ferreira, C. G., Tolis, C., & Giaccone, G. (1999) · Annals of Oncology · doi:10.1023/a:1008361818480 · Cited by 174
Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity
Wallace, M., Worrall, E. G., Pettersson, S., Hupp, T. R., & Ball, K. L. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.029 · Cited by 172
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
Xirodimas, D., Saville, M. K., Edling, C., Lane, D. P., & Laín, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204656 · Cited by 169
Self-citation
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 167
Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo
Saville, M. K., Sparks, A., Xirodimas, D. P., Wardrop, J., Stevenson, L. F., Bourdon, J.-C., Woods, Y. L., & Lane, D. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403362200 · Cited by 158
Self-citation
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation
Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J., & Herrlich, P. (1999) · Oncogene · doi:10.1038/sj.onc.1202480 · Cited by 151
Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction
Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 149
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 148
Self-citation
Hypophosphorylation of Mdm2 Augments p53 Stability
Blattner, C., Hay, T., Meek, D. W., & Lane, D. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6170-6182.2002 · Cited by 144
Self-citation
Discovering novel chemotherapeutic drugs for the third millennium
Garrett, M. D., & Workman, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00280-4 · Cited by 141
Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D2concept
Uversky, V. N. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.36 · Cited by 147
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht
Chêne, P., Fuchs, J. P., Bohn, J. A., Garcı́a-Echeverrı́a, C., Furet, P., & Fabbro, D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3738 · Cited by 139
Understanding p53 functions through p53 antibodies
Sabapathy, K., & Lane, D. P. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz010 · Cited by 139
Self-citation
RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer
Fang, S., Lorick, K. L., Jensen, J. P., & Weissman, A. M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00095-0 · Cited by 148
An Inhibitor of Nuclear Export Activates the p53 Response and Induces the Localization of HDM2 and p53 to U1A-Positive Nuclear Bodies Associated with the PODs
Laín, S., Midgley, C., Sparks, A., Lane, E. B., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4433 · Cited by 136
Self-citation
The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 137
Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chêne, P. (2004) · PubMed · Cited by 136
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 132
Molecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131
Inhibition of the p53-MDM2 Interaction: Targeting a Protein-Protein Interface
Chêne, P. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.20.2.1 · Cited by 153
Drugs Targeting Protein–Protein Interactions
Chêne, P. (2006) · ChemMedChem · doi:10.1002/cmdc.200600004 · Cited by 131
Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction
Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Obrecht, D., Mittl, P. R. E., Grütter, M. G., & Robinson, J. A. (2006) · ChemBioChem · doi:10.1002/cbic.200500452 · Cited by 129
The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation
Zilfou, J. T., Hoffman, W. H., Sank, M. J., George, D. L., & Murphy, M. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3974-3985.2001 · Cited by 129
Cocompartmentalization of p53 and Mdm2 Is a Major Determinant for Mdm2-Mediated Degradation of p53
Xirodimas, D. P., Stephen, C. W., & Lane, D. P. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5314 · Cited by 127
Self-citation
Therapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127
Self-citation
Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2
Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 125
Phage-displayed peptide libraries
Zwick, M. B., Shen, J., & Scott, J. K. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80017-7 · Cited by 126
Activation of the Cell Death Program by Nitric Oxide Involves Inhibition of the Proteasome
Glockzin, S., von Knethen, A., Scheffner, M., & Brüne, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19581 · Cited by 123
Keeping an old friend under control: regulation of p53 stability
Kubbutat, M. H. G., & Vousden, K. H. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01260-x · Cited by 122
Activation of p53 by roscovitine-mediated suppression of MDM2 expression
Lu, W., Chen, L., Peng, Y., & Chen, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204412 · Cited by 117
The Conformationally Flexible S9–S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo
Shimizu, H., Burch, L. R., Smith, A. J., Dornan, D., Wallace, M., Ball, K. L., & Hupp, T. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202296200 · Cited by 116
p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 117

Authors: Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P.
Affiliations: University of Dundee (GB)
Corresponding author: Lane, David P.
ORCID: Böttger, Angelika
Lane, David P.
Venue: Current Biology
Publisher: Elsevier BV
Published: 1997-11
Volume: 7
Issue: 11
Pages: 860-869
ISSN: 0960-9822 (ISSN-L)
DOI: 10.1016/s0960-9822(06)00374-5
OpenAlex: W2041568308
Cited by: 363
References: 37
Citations by year: 2024: 1 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 2 · 2015: 4 · 2014: 12 · 2013: 6 · 2012: 12
FWCI: 11.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 5737 d)
Locations: Current Biology (publishedVersion)
PubMed (publishedVersion)
Funders: European Commission
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: p53, MDM2, p53-MDM2 interaction, protein-protein interaction disruption, thioredoxin, p53 stabilization, transcriptional activation, cell cycle arrest, phage display peptides, DNA damage response, tumour suppressor
MeSH terms: Amino Acid Sequence, Animals, Binding, Competitive, Cell Cycle, Cell Line, Humans, Male, Molecular Sequence Data, Nuclear Proteins, Prostate, Protein Binding, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Thioredoxins, Transfection, Tumor Cells, Cultured, Protein Engineering, Transcriptional Activation, Tumor Suppressor Protein p53, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks